LONDON, UK (GlobalData), 26 July 2012 – A novel anti-TB drug cocktail generated encouraging results in a recent Phase II trial funded by the non-profit TB Alliance. The combination of three drugs (PA-824, moxifloxacin and pyrazinamide) was able to …
Hebei Xingang Pharmaceutical Co., Ltd.
Professional manufacturer of Rifampicin and Rifamycin Derivatives
LONDON, UK (GlobalData), 26 July 2012 – A novel anti-TB drug cocktail generated encouraging results in a recent Phase II trial funded by the non-profit TB Alliance. The combination of three drugs (PA-824, moxifloxacin and pyrazinamide) was able to …